ANACETRAPIB ( DrugBank: Anacetrapib )


1 disease
IDDisease name (Link within this page)Number of trials
79Homozygous familial hypercholesterolemia5

79. Homozygous familial hypercholesterolemia


Clinical trials : 145 Drugs : 114 - (DrugBank : 26) / Drug target genes : 8 - Drug target pathways : 17
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-002434-37-IT
(EUCTR)
16/07/201305/06/2013n.a.A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-WeekStudy to Assess the Efficacy and Tolerability of Anacetrapib When Added to OngoingLipid-Lowering Therapy in Adult Patients with Homozygous FamilialHypercholesterolemia (HoFH) - n.a. Homozygous Familial Hypercholesterolemia (HoFH)
MedDRA version: 14.1;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: Anacetrapib
Product Code: MK-0859
INN or Proposed INN: ANACETRAPIB
Other descriptive name: ANACETRAPIB
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncNULLNot RecruitingFemale: yes
Male: yes
45Phase 3United States;Czech Republic;Canada;Malaysia;Brazil;Israel;South Africa;Norway;United Kingdom;Italy
2EUCTR2012-002434-37-CZ
(EUCTR)
13/06/201328/12/2012n/aA Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-WeekStudy to Assess the Efficacy and Tolerability of Anacetrapib When Added to OngoingLipid-Lowering Therapy in Adult Patients with Homozygous FamilialHypercholesterolemia (HoFH) with a 52-Week Open-Label Extension Homozygous Familial Hypercholesterolemia (HoFH);Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: MK-0859
Product Code: (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’-
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncNULLNot RecruitingFemale: yes
Male: yes
45United States;Czech Republic;Canada;Malaysia;Australia;Israel;South Africa;Norway;United Kingdom
3NCT01841684
(ClinicalTrials.gov)
June 201324/4/2013Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)Hyperlipoproteinemia Type II;Homozygous Familial HypercholesterolemiaDrug: Anacetrapib;Drug: PlaceboMerck Sharp & Dohme Corp.NULLTerminated18 YearsN/ABoth2Phase 3United States;Canada;Germany;Israel;Italy;United Kingdom;Norway
4EUCTR2012-002434-37-GB
(EUCTR)
23/05/201323/11/2012n/aA Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients with Homozygous Familial Hypercholesterolemia (HoFH) with a 52-Week Open-Label Extension - Anacetrapib in Patients with Homozygous Familial Hypercholesterolemia Homozygous Familial Hypercholesterolemia (HoFH);Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: MK-0859
Product Code: (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’-
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncNULLNot Recruiting Female: yes
Male: yes
45 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited States;Czech Republic;Canada;Malaysia;Australia;Israel;South Africa;Norway;Italy;United Kingdom
5EUCTR2012-002434-37-NO
(EUCTR)
21/11/201226/11/2012n/aA Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-WeekStudy to Assess the Efficacy and Tolerability of Anacetrapib When Added to OngoingLipid-Lowering Therapy in Adult Patients with Homozygous FamilialHypercholesterolemia (HoFH) with a 52-Week Open-Label Extension Homozygous Familial Hypercholesterolemia (HoFH);Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Product Name: MK-0859
Product Code: (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’-
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., IncNULLNot RecruitingFemale: yes
Male: yes
45United States;Czech Republic;Canada;Malaysia;Australia;Israel;South Africa;Norway;United Kingdom